Indications
Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
Composition
- Active substance
- recombinant varicella zoster virus glycoprotein E
- International name (INN)
- herpes zoster vaccine (recombinant, adjuvanted)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Shingrix
- Active substance
- recombinant varicella zoster virus glycoprotein E
- ATC code
- J07BK03
- Therapeutic area